Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Ono Seeks Japan Nod for Malignant Mesothelioma for Opdivo
March 1, 2023
- Actemra Filed in Japan for CRS Induced by Cancer Treatment: Chugai
March 1, 2023
- Lecanemab Earns Priority Review Status in China: Eisai
March 1, 2023
- Japan Approves Pfizer’s Omicron-Tailored Vaccine for Ages 5-11
March 1, 2023
- Mitsubishi Chemical to Fix “Overextension” of Pharma Biz, Focus on 4 Therapeutic Areas, Japan/US: CEO
February 28, 2023
- Xocova Taken by Estimated 32,270 Patients as of Feb. 19: Shionogi
February 28, 2023
- Enhertu Approved in China for HER2 Positive Breast Cancer
February 28, 2023
- COVID-19 Drugs Haul Big Sales in 2022, Veklury Crosses 100 Billion Yen Line
February 27, 2023
- Pfizer Japan Files PARP Inhibitor Talazoparib for Breast and Prostate Cancer
February 27, 2023
- Astellas Presents Update on PI/II Study of AT845 for Late-Onset Pompe Disease
February 27, 2023
- Pfizer Japan Begins Amoxapine Recall, Ceases Shipments over Carcinogen Risks
February 27, 2023
- Ono Bags Right to Cue Biopharma’s Tregs-Inducing Bispecific Protein
February 24, 2023
- Shionogi’s Xocova Cuts Risks of Long COVID by 45%: Exploratory Data
February 24, 2023
- Opdivo Approved for NSCLC Neoadjuvant Use in Taiwan
February 24, 2023
- Teijin, Axcelead to Launch Drug Discovery Joint Venture
February 22, 2023
- Kidswell Bio Revs Up Biosimilar Push, G-Lasta, Eylea Follow-Ons in Development
February 22, 2023
- Pfizer Files RSV Vaccine in Japan
February 21, 2023
- FDA Target Date for Hot Flash Med Extended by 3 Months: Astellas
February 21, 2023
- Japan Approves Taisho’s Visceral Fat-Reducing Med as Nonprescription Drug
February 20, 2023
- US Patent Office Restarts PGR for Seagen Patent: Daiichi Sankyo
February 20, 2023
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…